GANX - NASDAQ
Gain Therapeutics, Inc.
$1.88
+4.7%Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
At a Glance
Live SnapshotGain Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gain Therapeutics, Inc. Income Statement
GANX • NASDAQ
| Gain Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
0.0 | 0.0 | 55.2K | 132.6K | 133.9K | 28.9K | 41.3K | 20.6K | |
GROSS PROFIT | ||||||||
(94K) | (0.0) | (0.0) | (8.2M) | (7.2M) | (0.0) | (0.0) | (0.0) | |
-94K | 0.0 | 55.2K | -8.1M | -7M | 28.9K | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||
(18.6M) | (20.4M) | (22.3M) | (9.7M) | (6.8M) | (3.5M) | (2.1M) | (1M) | |
(8.5M) | (9.6M) | (10.8M) | (9.7M) | (6.8M) | (1.2M) | (555.2K) | (222K) | |
(10.2M) | (10.8M) | (11.5M) | (8.5M) | (7.3M) | (2.3M) | (1.6M) | (826.9K) | |
-18.7M | -20.4M | -22.3M | -17.8M | -13.8M | -3.5M | -2.1M | -1M | |
PRE-TAX INCOME | ||||||||
244.4K | 357.1K | 494.2K | 375.4K | 12.5K | 3.6K | -20.5K | -52.5K | |
-94K | (0.0) | (0.0) | -8.5M | -7.4M | (0.0) | (0.0) | (0.0) | |
-589.3K | 476.2K | 64.9K | 279.3K | -60.4K | -92.8K | -86.2K | -67.4K | |
-19.3M | -19.9M | -22.2M | -17.5M | -13.9M | -3.6M | -2.2M | -1.1M | |
NET INCOME | ||||||||
(861.1K) | (536.8K) | (79.3K) | (93K) | (4K) | (5.4K) | (7.1K) | (9.8K) | |
-20.2M | -20.4M | -22.3M | -17.6M | -13.9M | -3.6M | -2.2M | -1.1M |
SEC Filings
GANX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 26, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 18, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 28, 2025 | November 28, 2025 | 2025 |
Related Guides
Continue your GANX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.